Pharmaceuticals company Indoco Remedies announced Q1FY27 results Consolidated Financial Highlights: Revenue from Operations for Q1FY27 stood at Rs 46,622 lakh, representing a growth of 2.26% QoQ from Rs 45,590 lakh in Q4FY26 and a 8.21% increase YoY compared to Rs 43,086 lakh in Q1FY26. Total Income for the quarter Q1FY27 was Rs 46,968 lakh, showing a marginal decrease of 1.24% QoQ from Rs 47,557 lakh in Q4FY26, and rising 6.43% YoY from Rs 44,130 lakh in Q1FY26. The company reported a Net Profit of Rs 6,544 lakh in Q1FY27, marking a recovery compared to a loss of Rs 2,368 lakh in Q4FY26 and a loss of Rs 3,635 lakh in Q1FY26. Earnings per share (EPS) for Q1FY27 was Rs 7.09, compared to Rs (2.57) in Q4FY26 and Rs (3.94) in Q1FY26. Standalone Financial Highlights: Revenue from Operations in Q1FY27 was Rs 40,812 lakh, reflecting a 4.88% QoQ decrease from Rs 42,906 lakh in Q4FY26 and a 5.84% YoY increase from Rs 38,561 lakh in Q1FY26. Total Income for Q1FY27 stood at Rs 41,344 lakh, down 10.02% from Rs 45,948 lakh in Q4FY26 and up 3.39% from Rs 39,989 lakh in Q1FY26. Net Profit for the quarter Q1FY27 reached Rs 8,232 lakh, significantly higher than Rs 2,735 lakh in Q4FY26 and showing a recovery from a loss of Rs 2,807 lakh in Q1FY26. Business Highlights: Exceptional Item: The company completed the slump sale of its Ophthalmic Business Division to Sunways (India) Private Limited during Q1FY27. This transaction resulted in a gain of Rs 9,734 lakh, which has been recognized as an exceptional item. Geographical Performance: India: Revenue from India in Q1FY27 was Rs 31,177 lakh, growing 26.15% QoQ from Rs 24,710 lakh and 12.22% YoY from Rs 27,783 lakh. Outside India: Revenue from international markets in Q1FY27 was Rs 15,445 lakh, down 26.01% QoQ from Rs 20,876 lakh and up 0.93% YoY from Rs 15,303 lakh. Aditi Panandikar, Managing Director, Indoco Remedies, said: “The Q1FY27 reflects the continued execution of our long-term strategy focused on deliverables from our core businesses despite a dynamic operating environment. The growth in this quarter is due to the resilient Domestic Formulation business, while our international formulations and API businesses continued to make steady progress.” Result PDF